NZ Malignant Haematology Research Review Issue 2

In this issue:
  -  Cilta-cel vs. standard care in lenalidomide-refractory MM
  -  Induction VRd vs. KRd in newly diagnosed MM
  -  Isatuximab-carfilzomibdexamethasone for relapsed MM
  -  PFS associated with DRd and VRd
  -  BCMA CAR T-cell therapies in older patients with MM
  -  Pirtobrutinib in chronic lymphocytic leukaemia
  -  Obesity in AML not associated with inferior response/survival
  -  Pembrolizumab in relapsed/ refractory PMBCL
  -  Lymphoma in pregnancy
  -  Intensive chemotherapy ± gemtuzumab ozogamicin for NPM1-mutated AML

Please login below to download this issue (PDF)